Varian Medical Systems is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies:

• Informatics software for managing comprehensive cancer clinics
• Radiotherapy centers
• Medical oncology practices

Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection.

More than 6,000 of Varian's medical linear accelerators for cancer radiotherapy and radiosurgery are in service around the world, treating tens of thousands of patients per day. The company also produces advanced brachytherapy systems for treating cancer.

Varian X-ray tubes are sold to most major diagnostic equipment manufacturers and cover a range of applications including advanced mammography and CT scanning. The company also produces the PaxScan line of real-time, digital X-ray image detectors, which are incorporated in many types of diagnostic imaging systems.

The company's Security and Inspection group is the market leader in high-energy X-ray devices for non-destructive testing and cargo screening.

Worldwide headquarters: Palo Alto, California, USA. Varian has manufacturing sites in North America, Europe, and China as well as approximately 70 sales and support offices around the world. Varian is proud to partner with Snow Everest Co., Ltd for exclusive distribution on emerging Myanmar market.

The Clinac iX is a streamlined, high-performance and reliable platform that incorporates a broad range of imaging and treatment options, including dynamic motion management. Every Clinac® linear accelerator is built on the new, high-performance iX platform, and every system can be custom configured. That means every facility always starts with the best and builds forward. This combination of quality and customization allows clinicians to meet the specific needs of each site, and to ensure that future treatment advances are always within reach.